Get the Stockscreener App
0.2143
0.89%
0.0019
Pre-market:
.21
-0.0043
-2.01%
Kala Bio Inc stock is traded at $0.2143, with a volume of 3.62M.
It is up +0.89% in the last 24 hours and down -46.96% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.2124
Open:
$0.2174
24h Volume:
3.62M
Relative Volume:
0.56
Market Cap:
$195.30M
Revenue:
$420.00K
Net Income/Loss:
$-35.84M
P/E Ratio:
-0.0361
EPS:
-5.9381
Net Cash Flow:
$-32.12M
1W Performance:
-15.13%
1M Performance:
-46.96%
6M Performance:
-98.82%
1Y Performance:
-96.80%
1-Day Range:
$0.2131
$0.2293
1-Week Range:
$0.2111
$0.2525
52-Week Range:
$0.2111
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.2143 | 193.57M | 420.00K | -35.84M | -32.12M | -5.9381 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Trading Action: Will KALA BIO Inc stock benefit from M A2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March - MarketBeat
Kala Bio rises on plans to leverage AI - MSN
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
FinancialContent$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - FinancialContent
KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
KALA Engages AI Technology for Advancing Psilocybin Drug Development - GuruFocus
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - Investing News Network
Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010 - TipRanks
Red Light Holland Engages Kala Bio’s Researgency.AI - GlobeNewswire
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - TMX Newsfile
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Stock Trend Capital Highlights Younet AI’s Exclusive Biotech Partnership with KALA BIO - TipRanks
KALA BIO to launch first commercial AI agent in two weeks - Investing.com Nigeria
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update - MarketBeat
Why Did KALA Stock Surge 25% Today? - Stocktwits
Form 144 KALA BIO For: 12 March By Investing.com - Investing.com Australia
Movement Recap: Does Dragonfly Energy Holdings Corp Equity Warrant have consistent dividend growthQuarterly Trade Report & Expert Curated Trade Ideas - baoquankhu1.vn
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Form 144 KALA BIO For: 12 March - Investing.com
After Hours 11 Mar 2026: KALA BIO (KALA NASDAQ) up 24.16% to $0.36, model sees upside - Meyka
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - The Globe and Mail
KALA BIO (KALA) Stock Jumps 70% After Pivoting to AI With ‘Palantir for Biotech’ Vision - MEXC
KALA BIO's 70% Surge: Flow Analysis of the AI Pivot - Bitget
Kala Bio Announces Launch Of First Commercial AI Product - marketscreener.com
KALA BIO (KALA) Stock Soars 70% on AI Agent Launch and ‘Palantir for Biotech’ Strategy - Blockonomi
Why Did KALA Stock Surge 70% In Pre-Market Today? - Asianet Newsable
Why Is Kala Bio Stock Soaring Wednesday?Kala Bio (NASDAQ:KALA) - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
KALA Announces Launch of First AI Product, Revolutionizing Biote - GuruFocus
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates - Bitget
KALA BIO to launch first commercial AI agent in two weeks By Investing.com - Investing.com India
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Stock Trend Capital Provides Younet AI Investment Update - TMX Newsfile
Younet AI inks exclusive biotech platform deal with KALA BIO - Stock Titan
Dividend Watch: Will KALA BIO Inc benefit from sector rotationProduct Launch & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
$167 Billion Invested in Biotech R&D is Underserved by AI, Offering Huge Opportunity for New On-Premises AI Infrastructure Platform from KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
$167 Billion Invested in Biotech R&D is Underserved by AI, - openPR.com
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
$167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA - PRLog
KALA Unveils AI Platform to Revolutionize Biotech Data Managemen - GuruFocus
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com Australia
What's Going On With KALA BIO Stock Wednesday?Kala Bio (NASDAQ:KALA) - Benzinga
KALA Bio launches on-premises AI platform for biotech sector - Investing.com Nigeria
Kala Bio, Inc Announces Exclusive License Agreement with Younet Ai for Proprietary Ai Research Platform - marketscreener.com
Kala Bio Launches AI Platform for Biotech Industry - Data Center Knowledge
KALA BIO Secures Exclusive Researgency AI Platform License - TipRanks
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):